Helios Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 29 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 32.33%
(FY 2023)
- Ebitda 32.33%
(FY 2023)
- Net Worth -10.96%
(FY 2023)
- Total Assets -9.95%
(FY 2023)
About Helios Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chirag Patel, Nilesh Patel, Dhruvkumar Patel, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24231GJ1995PTC025089
- Company No.
025089
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Mar 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Helios Pharmaceuticals?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chirag Patel  | Director | 07-Nov-2012 | Current |
| Nilesh Patel | Alternate Director | 15-Apr-2010 | Current |
| Dhruvkumar Patel | Director | 21-Mar-1995 | Current |
| Ashokkumar Patel | Director | 21-Mar-1995 | Current |
| Amrishkumar Patel | Director | 21-Mar-1995 | Current |
| Kirtikumar Patel | Director | 21-Mar-1995 | Current |
Financial Performance and Corporate Structure Insights of Helios Pharmaceuticals.
Helios Pharmaceuticals Pvt Ltd, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 32.33% increase in profit. The company's net worth observed a substantial decline by a decrease of 10.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Helios Pharmaceuticals?
In 2023, Helios Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- J P Tobacco Products Private LimitedActive 42 years 11 months
Chirag Patel, Nilesh Patel and 2 more are mutual person
- Parbhudas Kishoredas Tobacco Products Pvt LtdActive 53 years 2 months
Chirag Patel, Ashokkumar Patel and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Helios Pharmaceuticals?
Helios Pharmaceuticals has a workforce of 281 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Helios Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Helios Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
